CRV
NEUTRALCraven House Capital Plc: Notification of Major Shareholding Change
The investment company has received a notification of a change in major shareholding, with no clear impact on operations.
Craven House Capital
0.1750USD
0.00%
Market Cap
676.13k
Volume
305k
8976% of avg
P/E Ratio
EPS (TTM)
Beta
0.17
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p0.1750p0.4970p
0.1750p
CRV
BADCraven House Capital Reports Annual Loss Amid Strategic Portfolio Developments
The investment company reported an annual loss of $893,000 and negative equity, but highlighted strategic progress in its portfolio companies, including successful reverse takeovers and share distributions.
CRV
GOODCraven House Capital Boosts Portfolio with QuiaPeg Pharma Stake
Craven House Capital, an investment company, has boosted its portfolio with a stake in drug developer QuiaPeg Pharma.
CRV
NEUTRALMajor Shareholder Reduces Stake in Craven House Capital
Investment company sees shift in major shareholder
CRV
NEUTRALCraven House Capital Sees Shift in Major Shareholder
Financial services investment company sees shift in major shareholder
CRV
Craven House Capital Provides Update on Investee Companies
Craven House Capital plc provides an update on its investee companies, highlighting impairments and future prospects.
CRV
Craven House Capital's Investee Companies Garimon and Honeydog Terminate Exclusivity Agreement
Craven House Capital's investee companies Garimon and Honeydog terminate exclusivity agreement, ceasing work on proposed transaction.
CRV
Craven House Capital Announces Approval of Transaction with Bio Vitos
Craven House Capital announces approval of transaction with Bio Vitos, paving the way for completion in September 2023.